Affiliation:
1. Glycation, Oxidation and Disease Laboratory, Touro University California, Vallejo, CA 94592, USA
Abstract
The availability of sugar has expanded over the past 50 years, due to improved industrial processes and corn subsidies, particularly in the form of sweetened beverages. This correlates with a surge in the prevalence of cardiometabolic disorders, which has brought this issue back into the spotlight for public health. In this narrative review, we focus on the role of fructose in the genesis of cardiometabolic dyslipidemia (an increase in serum triglyceride-rich lipoproteins (TRL): VLDL, chylomicrons (CM), and their remnants) bringing together the most recent data on humans, which demonstrates the crucial interaction between glucose and fructose, increasing the synthesis while decreasing the catabolism of these particles in a synergistic downward spiral. After reviewing TRL metabolism, we discuss the fundamental principles governing the metabolism of fructose in the intestine and liver and the effects of dysregulated fructolysis, in conjunction with the activation of carbohydrate-responsive element-binding protein (ChREBP) by glucose and the resulting crosstalk. The first byproduct of fructose catabolism, fructose-1-P, is highlighted for its function as a signaling molecule that promotes fat synthesis. We emphasize the role of fructose/glucose interaction in the liver, which enhances de novo lipogenesis, triglyceride (TG) synthesis, and VLDL production. In addition, we draw attention to current research that demonstrates how fructose affects the activity of lipoprotein lipase by increasing the concentration of inhibitors such as apolipoprotein CIII (apoCIII) and angiopoietin-like protein 3 (ANGPTL3), which reduce the catabolism of VLDL and chylomicrons and cause the building up of their atherogenic remnants. The end outcome is a dual, synergistic, and harmful action that encourages atherogenesis. Thus, considering the growing concerns regarding the connection between sugar consumption and cardiometabolic disease, current research strongly supports the actions of public health organizations aimed at reducing sugar intake, including dietary guidance addressing “safe” limits for sugar consumption.
Reference152 articles.
1. How Bad Is Fructose?;Bray;Am. J. Clin. Nutr.,2007
2. Soft Drink Consumption and Obesity: It Is All about Fructose;Bray;Curr. Opin. Lipidol.,2010
3. Fructose: Pure, White, and Deadly? Fructose, by Any Other Name, Is a Health Hazard;Bray;J. Diabetes Sci. Technol.,2010
4. Fructose: Metabolic, Hedonic, and Societal Parallels with Ethanol;Lustig;J. Am. Diet. Assoc.,2010
5. Fast Food, Central Nervous System Insulin Resistance, and Obesity;Isganaitis;Arterioscler. Thromb. Vasc. Biol.,2005
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献